Here's what is coming soon to NeurologyLive®.
Every week, the NeurologyLive® staff prepares this preview of what to expect from our coverage. This week on NeurologyLive®, there are a number of hot topics that we will be posting on the website. As always, our weekly coverage extends beyond just these topics, so make sure to check out the rest of the site!
Click through the slides below to see what you can expect from our team this week:
The MJH Life Sciences Medical World News streaming channel is always streaming 24/7, so make sure to check out the channel for new episodes, and catch up on-demand with your favorites before the new episodes go live—but now you can catch all new content from season 5!
NeurologyLive® contributes regularly to all of our show offerings, so there is plenty of specialty-focused and outside area conversations, as well as more lighthearted content for you to view.
To catch up and check out what's on the Medical World News channel now, or check out hundreds of episodes on-demand, click here.
The NeurologyLive® February 2022 issue goes live this week! It includes feature articles by Adolfo Ramirez-Zamora, MD; Daniel Ackerman, MD, FAAN; and Crystal M. Proud, MD, and was led by guest editor-in-chief John Brandsema, MD. The issue covers topics in Parkinson disease, stroke, neuromuscular disorders, epilepsy, and much more—with a cover story on the ongoing shortage of neurologists.
To catch up on prior issues, click here.
The latest in our NeuroVoices series, dedicated to conversations with leaders in the neurology community, goes live on Wednesday, February 16. This week, it will feature a conversation with George Grossberg, MD, Samuel W. Fordyce professor and director of Geriatric Psychiatry, Saint Louis University School of Medicine, who shared insight into his recent work evaluating the use of telemedicine to assess and manage psychosis in the long-term care of patients with neurodegenerative diseases.
To check out the prior NeuroVoices conversations, click here.
IN CASE YOU MISSED IT: The 57th episode of the NeurologyLive® Mind Moments™ podcast premiered on Friday, February 11! The show features an exclusive conversation with Dhanashri P. Miskin MD, clinical assistant professor of neurology, Thomas Jefferson University Hospitals, who will share her insight into the current state of care for patients with multiple sclerosis (MS) who experience cognitive impairment, as well as the challenges in treating this symptom in MS.
To listen and subscribe on your favorite podcast player, click here.
IN CASE YOU MISSED IT: The NeurologyLive® webinar, "Demystifying Multiple Sclerosis Etiology: The Role of Epstein-Barr Virus," is live! The series premiered on Friday, January 28, but is still FREE to register for and view!
New research supports a significant and causative relationship between infection with Epstein-Barr virus and the development of multiple sclerosis. This expert-led panel discussion, moderated by Scott Newsome, DO, will review the findings and discuss the implications for patients with multiple sclerosis, the health care providers who treat them, and the greater neurology community.
To catch up on the series, click here.
IN CASE YOU MISSED IT: According to the National Institutes of Health’s clinical trials registry, more than 400 clinical trials of therapies designed to treat neurologic diseases are actively ongoing across phases 1 through 3 . Of those, more than 200 are in phase 3 development. Notably, many investigational therapies are addressing diseases with a high unmet clinical need, with either no currently available disease-modifying therapies or very limited options.
With so much activity in the clinical development pipeline, keeping up with the latest findings can sometimes be difficult. Here are 5 critical trials with expected data readouts in 2022 that NeurologyLive® will have its eye on.
IN CASE YOU MISSED IT: The finals episodes featuring Jeffrey L. Cummings, MD, ScD, are expected to go live this week for this Insights series! In it, he discusses Alzheimer disease and the advances recently made to improve the treatment landscape, specifically with aducanumab (Aduhelm; Biogen). Cummings offers perspectives on the pathophysiology of the disease and the current testing options available to assess amyloid-beta levels.
To catch up on the series, click here.